Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study

Stephen K. Williamson, John J. Crowley, Robert Livingston, Alexander Hantel, James H. Doroshow

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Piroxantrone demonstrated no activity in 17 eligible patients. Toxicity was acceptable and dose escalations were performed. With only 35% (6/17) of patients experiencing grade 2 or greater granulocytopenia the study might be criticized for utilizing a less than optimal dose of piroxantrone. Based on this trial, piroxantrone is not felt to have significant antitumor activity against advanced non-small cell carcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)29-30
Number of pages2
JournalInvestigational New Drugs
Volume10
Issue number1
DOIs
StatePublished - Mar 1992

Keywords

  • lung cancer
  • non-small cell
  • phase II
  • piroxantrone

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung - A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this